Tamoxifen is an ERα antagonist that competitively inhibits the interaction of estrogen with ERα3 thus, most breast cancers can be treated with endocrine therapy using anti-estrogens such as tamoxifen or aromatase inhibitors after surgery or radiation for primary prevention strategy4, 5. The gene discussed is CYP19A1; the disease is breast carcinoma.